# EDGAR Filing Document

**Accession Number:** 0001563577
**File Stem:** 0001193125-26-055919
**Filing Date:** 2026-2
**Character Count:** 9217
**Document Hash:** c95324c98f4a60c56cf6c0757ef9535e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-055919.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0001193125-26-055919

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260212

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001563577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461454898
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39114
- **FILM NUMBER:** 26645213

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 610-725-1500

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): February 12, 2026

## GALERA THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39114** | **46-1454898** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

#### 101 Lindenwood Drive, Suite 225

#### Malvern, PA 19355

#### (Address of principal executive offices) (Zip Code)
(610) 725-1500

#### (Registrant's telephone number, include area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.001 par value per share | GRTX | OTCQB Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.03** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.** |

---

On February 12, 2026, Galera Therapeutics, Inc. (the "Company") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the "Certificate of Designation") with the Secretary of State of Delaware. The Amendment provides that, in the sole discretion of the Company's board of directors (the "Board"), the Company may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Preferred Stock into a number of shares of Common Stock calculated based on the Conversion Ratio (as defined in the Certificate of Designation). The Amendment was approved by the Board and by unanimous written consent of the holders of the Company's Series B Non-Voting Preferred Stock.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3.1 hereto and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 3.1 | [Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock](d60666dex31.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | GALERA THERAPEUTICS, INC. | GALERA THERAPEUTICS, INC. |
| Date: February 18, 2026 | By: | /s/ J. Mel Sorensen, M.D. |
|  |  | J. Mel Sorensen, M.D. |
|  |  | President and Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1** 

**GALERA THERAPEUTICS, INC.** 

**CERTIFICATE OF AMENDMENT TO** 

**CERTIFICATE OF DESIGNATION OF PREFERENCES,** 

**RIGHTS AND LIMITATIONS** 

**OF** 

**SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK** 

Galera Therapeutics, Inc. (the "**Corporation**"), a corporation organized and existing under the General Corporation Law of the State Delaware (as amended, the "**DGCL**"), hereby certifies as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Corporation's Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the "**Certificate of Designation**") was filed with the Secretary of State of the State of Delaware on December 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Pursuant to the provisions of Sections 151 and 242 of the DGCL and the authority vested in the board of directors of the Corporation (the "**Board**") by the Restated Certificate of Incorporation of the Corporation filed with the Secretary of State of the State of Delaware on November 12, 2019 (the "**Restated Certificate**"), the Board has duly adopted resolutions providing for the amendment of the Certificate of Designation as provided for hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the holders of the Series B Non-Voting Convertible Preferred Stock of the Corporation for their consent in accordance with the Certificate of Designation, and was duly adopted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. This Certificate of Amendment hereby amends the Certificate of Designation by inserting a new Section 6.6 that reads as follows:

"6.6 <u>Mandatory Conversion</u>. At any time, in the sole discretion of the Board of Directors, the Corporation may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Preferred Stock into a number of shares of Common Stock calculated based on the Conversion Ratio (a "**Mandatory Conversion**"). The Corporation shall effect any Mandatory Conversion by delivering to each Holder a written notice (a "**Mandatory Conversion Notice**") at least one (1) Trading Day prior to the date specified therein for such conversion (the "**Mandatory Conversion Date**"), which Mandatory Conversion Notice shall (a) state that the Corporation is exercising its right to effect a Mandatory Conversion pursuant to this <u>Section</u> <u>6.6</u>, (b) specify the Mandatory Conversion Date, and (c) set forth the number of shares of Series B Non-Voting Preferred Stock to be converted and the number of shares of Common Stock to result from such conversion on the Mandatory Conversion Date. Except as expressly provided in this <u>Section</u> <u>6.6</u>, the mechanics and timing for the issuance and delivery of the shares of Common Stock issuable upon a Mandatory Conversion shall be as set forth in <u>Section</u> <u>6.4</u>, *mutatis mutandis*, as if the Holder had delivered a Notice of Conversion on the Mandatory Conversion Date. The provisions of <u>Section</u> <u>6.3</u>, including the Beneficial Ownership Limitation, shall not apply to any Mandatory Conversion pursuant to this <u>Section</u> <u>6.6</u>.

\* \* \* \* \* \* \*

------

**IN WITNESS WHEREOF**, the Corporation has executed this Certificate of Amendment to Certificate of Designation as of February 12, 2026.

---

| | |
|:---|:---|
| **GALERA THERAPEUTICS, INC.** | **GALERA THERAPEUTICS, INC.** |
| By: | /s/ J. Mel Sorensen |
|  | Name: J. Mel Sorensen |
|  | Title: President and Chief Executive Officer |

---